mCRPC treatment sequencing: Need for optimal therapy at the earliest opportunity

Challenges in high-risk NMIBC: Addressing current unmet needs to optimise patient care

Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts response in muscle-invasive bladder cancer

EAU 2026: Updates in NMIBC

Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab does not improve outcomes in advanced UC

Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer

Ultra-sensitive ctDNA detects residual disease and predicts recurrence early in RCC

Cabozantinib plus nivolumab and ipilimumab improves response in low GDS mRCC while high GDS predicts worse survival

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer

Microplastics found at higher levels in prostate cancer tissue compared to benign tissue

AMVAC plus nivolumab in muscle-invasive bladder cancer preserves bladder and predicts metastatic control with ctDNA

Real-world cardiovascular risks with novel hormonal therapies in advanced prostate cancer